Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial S
Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products
TORONTO--(BUSINESS WIRE)-- Easton Pharmaceuticals (OTC-PINK:EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces it has ordered specialized ingredients from its various suppliers for the purpose of creating final batches, trial and test samples of its reformulated Viorra and other recently added portfolio products.
After undergoing an approval process from its suppliers and distributors of Hyaluronic Acid in Japan and other ingredients from other suppliers, Easton was recently given the go ahead to be able to order and receive ingredients in bulk to create final batch trial and test samples followed by an anticipated marketing program to not only begin selling its products to the general public in North America, but the expected re-start of initiatives in various Latin American markets.
As previously announced, the company has reformulated various parts of its product line starting with its flagship product "Viorra" and its transdermal delivery system. In addition to Viorra, the company has introduced three new OTC products which include a topical OTC wound healing product, a topically applied pain gel and a motion sickness product, all based around and encompassing Hyaluronic Acid as its main active ingredient. A specialized form of Hyaluronic Acid can only be obtained through one producer in Japan with a certain amount of batches only made a few times a year.
Final packaging, naming rights and labeling are to be introduced very shortly. This will be followed by the anticipated marketing of the products on its soon to be revamped website which will coincide with its corporate name change from Easton to Ashley Biomedical Inc. Easton Pharmaceuticals believes there exists a demand and substantial opportunities in not only North America, but in various latin American and east Asian markets for Viorra and its other products. Easton intends on delivering sample trial product including final packaging to potential south latin market distributors through various consultants. It must then follow an approval protocol which is considered considerably shorter than in North America.
In other developments, Easton has also entered into discussions with the owner of a product for a possible 50% purchase of a potential drug, which presently has patents for the treatment of Female Sexual Arousal Disorder. This drug encompasses Alprostadil as its main ingredient, which is an FDA approved product that is a proven and extremely effective vasodilator. When used with the companies own delivery system, Easton believes this proposed product can be a very effective potential drug for the treatment of Female Sexual Arousal Disorder as well an effective treatment for men, which can be used as an alternative to its OTC products. Any such products would need to be approved by the FDA after undergoing rigorous FDA clinical trials. Additional updates on this initiative to be disclosed as they become available.
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to female and male sexual dysfunction, treatment of certain pain, wound healing, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's updated gel formulation is an innovative and thought to be unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Media and Investor Relations:email@example.comfirstname.lastname@example.org
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
Media and Investor Relations
KEYWORDS: North America Canada
The article Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.